NASDAQ · GTBP
GT Biopharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GTBP: Nov 13, 2026
GT Biopharma, Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-2.5. The reported EPS for the same quarter last year was $-20.75.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-2.50 | $-2.50 | $-2.50 | 1 |
| Dec 2026 | $-2.50 | $-2.50 | $-2.50 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · Quiver Quantitative- Fintel · Sep 15, 11:26 AM EDTGT Biopharma Consensus Price Target Raised 2,400% to $76.50The average one-year price target for GT Biopharma (NASDAQCM:GTBP) has been revised to $76.50 / share. This is an increase of 2,400.00% from the prior estimate of $3.06 dated August 25, 2026. These figures represent aggregate analyst targets and do not constitute a recommendatio
- RTTNews · Sep 15, 10:52 AM EDTGT Biopharma's GTB-5550 Secures FDA IND Clearance For Multiple Myeloma; Stock Down(RTTNews) – GT Biopharma, Inc. (GTBP), a clinical stage immuno-oncology company developing natural killer (NK) cell engager therapies, announced that the U.S. FDA has cleared a new IND application for GTB-5550 in multiple myeloma under an investigator sponsored trial protocol.
- RTTNews · May 15, 11:53 AM EDTGT Biopharma Records Q1 Loss Of $2 Mln; Advances GTB-3650 In Phase 1 Trial For Leukemia(RTTNews) – GT Biopharma Inc. (GTBP), a clinical-stage immuno-oncology company, on Friday announced first quarter results and provided updates on its developing pipeline.
- RTTNews · May 14, 11:09 AM EDTGT Biopharma Doses First Patient In Phase 1 Trial Of GTB-5550 Of Solid Tumors; Stock Up(RTTNews) – GT Biopharma, Inc. (GTBP) announced that the first patient has been dosed in its Phase 1 basket trial evaluating GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors. The milestone marks the third TriKE candidate to enter clinical testing and e
- Zacks · Mar 16, 12:00 PM EDTGT Biopharma (GTBP) Upgraded to Buy: Here's What You Should KnowGT Biopharma (GTBP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Mar 12, 9:55 AM EDTGT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?GT Biopharma (GTBP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- RTTNews · Jan 15, 10:41 AM ESTGT Biopharma Submits IND For GTB-5550 TriKE, Targeting B7-H3 Solid Tumors(RTTNews) – GT Biopharma, Inc. (GTBP) has submitted its investigational new drug (IND) application to the U.S. FDA for GTB-5550 TriKE, a novel natural killer (NK) cell engager designed to target B7-H3 expressing solid tumors.
- RTTNews · Jan 15, 9:11 AM ESTGT Biopharma Submits IND For GTB-5550 TriKE To Treat Solid Tumors(RTTNews) – GT Biopharma, Inc. (GTBP) on Thursday said it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for GTB-5550 TriKE, designed to target B7-H3 expressing solid tumor cancers.
- Quiver Quantitative · Jun 13, 9:12 AM EDTGT Biopharma, Inc. Appoints David C. Mun-Gavin to Board of DirectorsGT Biopharma appoints David C. Mun-Gavin to its Board of Directors, enhancing its leadership in immuno-oncology development.
- Quiver Quantitative · May 19, 9:13 AM EDTGT Biopharma, Inc. Advances to Cohort 2 in Phase 1 Trial of GTB-3650 Following Successful Safety Review of Cohort 1GT Biopharma reports no safety issues in Phase 1 Cohort 1, progressing to Cohort 2 for GTB-3650 trial.
- BNK Invest · Apr 10, 9:40 AM EDTSum Up The Parts: DFSU Could Be Worth $44Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself.
- Quiver Quantitative · Mar 4, 7:12 AM ESTGT Biopharma's Dr. Jeffrey Miller to Present on Tri-Specific Killer Engagers at Innate Killer SummitGT Biopharma announces Dr. Jeffrey Miller's participation at the Innate Killer Summit, discussing advancements in NK cell therapy.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for GT Biopharma, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.